Chemokines are a family of secreted proteins, which play an important role in the mediation of inflammation and chemotaxis of white blood cells [13] . Increasing evidence suggests that these cytokines and their receptors are closely related to tumor biology [46] . Early studies have found that chemokines and chemokine receptors play a role in inflammation and development. While at present, they are believed to contribute to the migration, proliferation, and survival of tumor cells. Complex microenvironments created by chemokines, chemokine receptors, and related molecules provide favorable conditions for sending tumor cells 耶homing爷 in the transfer process and for rapid growth afterward [5] . In this article, we mainly focus on recent progress in the role of CXCR7 in the occurrence and development of a variety of tumors.
Chemokines are small soluble molecules (814 kDa) secreted by different types of cells, which can mediate the directional movement of cells and chemotaxis by binding to Gproteincoupled receptors on the cell surface [7] . Different chemokines can combine and activate corresponding chemokine receptors on neutrophils, lymphocytes, endothelial cells, and epithelial cells. At this writing, more than 50 chemokines and 20 chemokine receptors have been found. Members of the chemokine family are divided into four subtypes (CXC, CC, C, and CX3C) depending on the inserts between their two conserved cysteine residues at the N terminus. A large number of studies have confirmed that chemokines can mediate the inflammatory response, chemotaxis in leukocytes, and tissuespecific 耶homing爷 of T lymphocytes, and promote tumor progression and metastasis [6, 8] . Tumor cells and stromal cells can generate a large number of chemokines through autocrine and paracrine signalling, and these chemokines can also bind with high affinity to the chemokine receptors of tumor cells and the stromal cell surface. Activation of most chemokines can switch on the inflow of calcium ion channels, activate the signaling pathways of protein Kinase C (PKC), PI3K, PLC茁 , src family tyrosine kinase (SFK), and so on, and induce tumor cell directional transfer and the process of chemotaxis [9] . Therefore, chemokines and their receptors might work as therapeutic targets, and a new treatment might be established to control tumor occurrence and development by activating or antagonizing the signaltransduction pathway of chemokine receptors. CXCR7, formerly known as RDC1, was first cloned from a dog cloned DNA (cDNA) library and presumed to be the G proteincoupled receptor (GPCR) of vasoactive intestinal peptide (VIP). However, the combination of VIP and RDC1 was soon challenged, and replaced by the assumption that RDC1 might be an adrenergic receptor, but this inference was also disconfirmed shortly thereafter [1014] . RDC1 is highly conserved in mammals (human, mouse, rat, dog). In mice, it is located on chromosome 1 with CXCR4, 窑Review窑 CXCR2, and CXCR1, while in huma ns, its counterpart gene is located on chromosome 2 with CXCR4, CXCR2, and CXCR1. In addition, like CXCR4, RDC1 can be used as a coreceptor in the HIV infection of CD4positive T cells [15] . These results have prompted the idea that RDC1 has many similarities with CXC receptors. Recently, Balabanian . [16] confirmed that RDC1 could bind to CXCL12 with high affinity, and pointed out that RDC1 was the second chemokine receptor of CXCL12, for the first time renaming RDC1 to CXCR7.
This finding broke the longstanding assumption that CXCR4 was the only receptor specific to CXCL12. As the second receptor for CXCL12, CXCR7 has been widely studied for its role in tumorigenesis and tumor development.
As a membraneassociated receptor protein, CXCR7 expresses on the surface of many tumor cells, activated endothelial cells, and fetal liver cells, but rarely in other normal cells. Current studies have found that CXCR7 expressed in a variety of human tumor cell lines, including breast cancer, cervical cancer, glioma, lung cancer, and so on [1719] . According to immunohistochemical staining, CXCR7 expression was detected in the primary sites of patient tissue samples of breast cancer, lung cancer (including squamous cell carcinoma and adenocarcinoma), rhabdomyosarcoma, cervical cancer, kidney cancer, esophageal cancer, and melanoma [17] . Recently, we stained tissue microarray of prostate cancer, and found for the first time that CXCR7 expression in normal prostate tissue was fairly low, but its expression was very high in the primary sites of prostate cancer, metastatic tumors in the bladder, liver, bone, lymph nodes, cerebral dura mater, and so on [20] . To clarify whether CXCR7 was related to tumor progression, we compared the CXCR7 staining conditions of prostate cancer tissue with different Gleason scores. The statistical results showed that as tumors progressed and as metastases emerged, pathologic scores went higher and CXCR7 expression also increased accordingly. A recent study found that in patients with pathologic grade I level nonsmall cell lung cancer, high levels of CXCR7 expression were related to metastatic recurrence [21] . These findings suggest that CXCR7 is closely related to tumor occurrence and development.
Burns
. [19] found that the proliferation ability of the human breast cancer cell line MDAMB435s with CXCR7 expression was markedly enhanced, when compared with a wildtype cell line control group. The total cell numbers were close in the two groups, but wildtype cell lines had a higher proportion of cell death. As shown in Annexin V apoptosis detection, CXCR7 was found to enhance the total number mainly by inhibiting cell apoptosis, rather than by increasing cell proliferation. However, Meijer . [22] proposed that in different types of tumor cells, the situation is not entirely consistent, and CXCR7 played an important role in switching on cell proliferation in mouse colon cancer and pancreat ic cancer cell lines. Our studies found that for prostate cancer cells that overexpressed CXCR7, the proliferation rate of prostate cell lines increased, and the corresponding reduction in the expression of CXCR7 suppressed their proliferation; while the overexpression of CXCR7 suppressed induced apoptosis in prostate cancer cells [20] . These findings show that CXCR7 expression in tumor cells is closely related to their proliferation and apoptosis.
The first step of tumor metastasis is adhesion between tumor cells and extracellular matrix. Both Burns . and we have found that CXCR7 affected adhesion between tumor cells and endothelial cells, and cells with highly expressed CXCR7 had a stronger adhesion ability compared those with no or low CXCR7 expression [19, 20] . Once the tumor cells adhere closely to the endothelial cells, they must pass through the extracellular matrix layer to establish metastatic tumors. using extracellular matrix invasion assays, we found that the overexpression of CXCR7 can significantly increase the invasive ability of prostate cancer cells [20] . These results suggest that CXCR7 expression in tumor cells could control adhesion and invasion.
By immunohistochemical staining, Miao . [17] found in a mouse model of breast cancer where CXCR7 protein was expressed in tumorassociated blood vessels, further testing of clinical specimens revealed that CXCR7 had a higher positive expression rate in breast cancerrelated blood vessels, while in the normal breast tissue of patients with breast cancer, the expression of CXCR7 was hardly found in blood vessels. These results are consistent in clinical biopsy samples of lung, ovarian, kidney, bladder cancer, and bile duct epithelial carcinoma. Madden .
[23] obtained similar results using in situ hybridization staining methods in gliomas and brainrelated arteries of normal tissue.
Our studies found that the overexpression of CXCR7 in prostate cancer cells caused the production of more IL8 and vascular endothelial growth factor (VEGF), and the corresponding reduction in the expression of CXCR7 reduced their secretion [20] . IL8 and VEGF have been confirmed as playing important parts in the formation of vascular systems that supply tumor growth and solid tumor development. In prostate cancer tissue, we validated that the expression of CXCR7 was correlated with tumorgenesis of prostate cancer and new blood vessels. These results suggested that CXCR7 might be involved in tumor angiogenesis by regulating process that lead up to proangiogenic factor (for example, VEGF, IL8) expression.
To figure out the CXCR7related potential target genes and signaltransduction pathway, we used gene microarray and discovered signaling molecules whose expression changed with CXCR7 [20] , such as cell adhesion molecule fibronectin (fibronectin 1), cadherin 11 (CDH11), CD44 tumor invasionrelated molecules, metallopro teinases (MMP3, MMP10, MMP11), the previously mentioned proangiogenic factors (IL8 and VEGF), and the signaltransduction pathway involved TGF茁 1, FGFR4, and so on. These target genes are closely related to tumor occurrence and development. Among them, CD44 expressed in a variety of tumors, and by regulating the extracellular receptor kinase (ERK) and Rac signaling pathways, CD44 antigens can regulate cell proliferation and solid tumor migration [24, 25] . TGF茁 1, as a tumor suppressor gene, was confirmed based on in vivo and in vitro experiments that it played very important roles in cell proliferation, tumor progression, and angiogenesis, partially by inhibiting the activation of CREB and the expression of Cyclin D1 [26] . Currently, research regarding the upstream regulatory genes that target CXCR7 have been carried out. Van Rechem . [27] confirmed that CXCR7 was a direct downstream target gene of the tumorsuppressor gene HIC1. According to their results that HIC1 is a direct inhibitor of CXCR7, when HIC1 expression was missing in tumors, the expressionenhanced CXCR7 might be involved in and influence tumor development. The activation of CXCR7 by CXCL12 could stimulate cell proliferation and increase both cell survival and cell adhesion properties, but it did not cause an inflow of intracellular calcium ions [17, 19] . Although the GPCRmediated signaltransduction function of CXCR7 remains controversial and does not participate in lymphocytes homing. The research of our and other groups suggest that CXCR7 and CXCR4 might form functional heterodimers to enhance CXCL12induced signal transduction [28] , and could activate the AKT signaltransduction pathway [20] . Levoye . [29] further confirmed this view. They found that when CXCR4 coexpressed with CXCR7, CXCR7 could induce structural rearrangements of the preassembled CXCR4/G琢 i protein complex and disrupt CXCR4promoted activation of the G琢 i protein and an influx of calcium. Therefore the interaction between CXCR7 and CXCL12 might be mediated by its own unusual signaling pathway of CXCR7 or through the formation of heterodimers with CXCR4 to regulate the activity of CXCR4. In addition, the conformational change of heterodimers will also affect the pharmacologic characteristics of CXCR7. Clearly, we need further indepth research in this area.
At present, research on CXCR7 has been concerned with its role in tumorigenesis and the development of a variety of tumors. There have been a number of invivo experiments performed to explore the feasibility of CXCR7 as a tumortargeted therapy. Miao . [17] used RNA interference technology to silence the expression of CXCR7 and found that inhibiting its expression could significantly reduce the volume and weight of primary tumors in breast and lung cancers, and inhibit lung metastasis in patients with breast cancer. Burns . [19] used the small molecule CXCR7 antagonist CCX754 to deal with mice with lymphoma and found that antagonizing the expression of CXCR7 could significantly improve the survival rate of mice. Indepth studies also found that inhibiting the expression of CXCR7 reduced tumor size as well as the level of tumor vascularization. Based on invivo and invitro experiments, we also found that inhibiting the expression of CXCR7 could reduce prostate tumorassociated angiogenesis [20] . However, Meijer . [22] found that using models of subcutaneous tumor implantation and lung cancer metastasis, CXCR7 did not significantly affect the tumor growth rate in vivo in some cases [22] and thus they proposed that CXCR7 inhibited tumor occurrence and development mainly in tissue with high CXCL12 expression, in tumor cells with CXCL12 autocrine signaling, or in tumors at specific developmental stages.
In addition, cancerrelated signaltransduction pathways and regulatory mechanisms of CXCR7 need indepth research. Fortunately, the latest research in zebra fish, an experimental model with a mature understanding of biologic development, found that the regulation of the expression of chemotactic factors in both CXCR7 and CXCR4 could interact with the Wnt/bcatenin and Fgf signaling pathways to control the cell selective migration [30] . Moreover, a study using a mouse model of acute renal injury found that CXCR7 was a key point in CXCL12mediated survival of renal progenitor cells and in the migration of endothelial cells, and that CXCR4 was not involved in these processes [31] , which expanded the understanding of the different functions of CXCR4 and CXCR7.
Currently, we have very limited knowledge on the interaction and mutual regulation among CXCL12, CXCR4, and CXCR7, and, the structural and functional similarities/differences between CXCR4 and CXCR7. These will direct the next steps in the research. In clinical applications, the development of stable and effective CXCR7 antagonist drugs with fewer side effects will become a new focus for tumor gene therapy research, which might open up new roads for the individual treatment of cancer patients.
